Last updated: July 17, 2026

Application No. 18/449,460

ERBB-2 AND ERBB3 BINDING BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF CELLS THAT HAVE AN NRG1 FUSION GENE

Non-Final OA

Filed

Aug 14, 2023

Priority

Mar 31, 2017 — EU 17164292.9 +2 more

Examiner

LI, RUIXIANG

Art Unit

1674

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Merus N V

OA Round

1 (Non-Final)

This examiner grants 59% of cases after interview

— +19.0% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 1023 resolved cases, 2023–2026

Examiner Intelligence

LI, RUIXIANG View full profile →

Grants 59% of resolved cases

Career Allowance Rate

608 granted / 1023 resolved

-0.6% vs TC avg

Strong +19% interview lift

Without

With

+19.0%

Interview Lift

resolved cases with interview

Typical timeline

2y 9m

Avg Prosecution

38 currently pending

Career history

1054

Total Applications

across all art units

Statute-Specific Performance

§101

1.3%

-38.7% vs TC avg

§103

30.4%

-9.6% vs TC avg

§102

18.9%

-21.1% vs TC avg

§112

40.9%

+0.9% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1023 resolved cases

Prosecution Timeline

Aug 14, 2023

Application Filed

Jun 05, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/846,709

Patent 12679890

ANTI-CLAUDIN 18 ANTIBODIES AND METHODS OF USE THEREOF

4y 0m to grant Granted Jul 14, 2026

18/050,970

Patent 12679895

RECOMBINANT ANTIBODY HAVING UNIQUE GLYCAN PROFILE PRODUCED BY CHO HOST CELL WITH EDITED GENOME AND PREPARATION METHOD THEREOF

3y 8m to grant Granted Jul 14, 2026

18/182,242

Patent 12679897

MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2

3y 4m to grant Granted Jul 14, 2026

18/337,737

Patent 12673998

ALK7 Binding Proteins and Uses Thereof

3y 0m to grant Granted Jul 07, 2026

18/446,795

Patent 12668638

ANTIBODIES THAT BIND EGFR AND CMET

2y 10m to grant Granted Jun 30, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

59%

Grant Probability

78%

With Interview (+19.0%)

2y 9m (~0m remaining)

Median Time to Grant

Low

PTA Risk

Based on 1023 resolved cases by this examiner. Grant probability derived from career allowance rate.